-
Hengrui new drugs aim at this 7 billion market Qilu, Kelunxiti new products
Time of Update: 2021-04-23
Medical Network, April 20, April 15th, NMPA official website updated the drug approval information, Xingqi Eye Medicine, Qilu Pharmaceutical and Jiangxi Kelun Pharmaceutical have all been approved for new eye drops; on April 16, Hengruizi The company Chengdu Shengdi Pharmaceutical has applied for the clinical trial of HR19034 eye drops 2.
-
Hisun Pharmaceutical Tofacitib Citrate Tablets Obtained Drug Registration Certificate
Time of Update: 2021-04-23
Hisun Pharmaceutical's tofacitib citrate tablets were approved by the State Food and Drug Administration according to the new category 4, and they were deemed to have passed the consistency evaluation.
-
Shanghai Pharmaceutical Enalapril Maleate Tablets Passed the Consistency Evaluation
Time of Update: 2021-04-23
On April 19, Shanghai Pharmaceuticals issued an announcement stating that Xinya Minhang, its holding subsidiary, had received the "Notice of Approval of Drug Supplement Application" (notice) issued by the State Food and Drug Administration regarding enalapril maleate tablets (5mg, 10mg).
-
The prices of these Chinese medicinal materials have increased (list attached)
Time of Update: 2021-04-23
Medical Network News on April 20 The prices of these Chinese medicines are rising Yesterday, the Pharmaceutical News Agency released the ranking list of Chinese medicinal materials price increase as of April 18 in Bozhou market.
-
Five ways to focus on monitoring drugs!
Time of Update: 2021-04-23
Open up a "second battlefield" For pharmaceutical companies, the restricted use of drugs due to key monitoring, ranging from a sharp decline in sales performance, to a rupture of the capital chain and falling to death.
-
The difference between Liuwei Dihuang Wan and Zhibai Dihuang Wan
Time of Update: 2021-04-23
So, what is the difference between Liuwei Dihuang Wan and Zhibai Dihuang Wan?Although both drugs belong to the traditional classic prescriptions for nourishing yin and tonifying the kidney, there are differences in clinical application due to the difference in the ingredients of the drugs.
-
Panlong Pharmaceutical cancels its wholly-owned subsidiary
Time of Update: 2021-04-23
According to the 2020 annual performance report of Panlong Group, during the reporting period, the company achieved operating income of 670,058,900 yuan, an increase of 9.
73% over the same period of the previous year; realized operating profit of 90,465,200 yuan, an increase of 4.
-
The fifth batch of national procurement reports: 60 varieties are involved, more than half of the injections!
Time of Update: 2021-04-23
Medical Network, April 16 News On April 15, the "Notice on Reporting the Purchasing Data of the Fifth Batch of National Organizations for Centralized Procurement of Drugs" circulated in the industry, which means that the fifth batch of national procurement officially kicked off.
-
Sage and Bojian SAGE-324 Phase II tremor test reached the primary endpoint
Time of Update: 2021-04-23
The results of the test showed that in the KINETIC trial (n=67), compared with placebo, patients received the GABAA receptor positive modulator SAGE-324 for 29 days after treatment, the basic tremor rating scale (TETRAS) performance subscale item 4 In the upper extremity tremor score, the primary endpoint of statistically significant reduction was reached (p=0.
-
The first STING agonist approved for clinical use
Time of Update: 2021-04-23
So companies such as GSK began to develop second-generation, non-cyclic dinucleotide small molecule STING agonists.
There are currently three companies including GSK, Taketa, Silicon Therapeutics and other companies developing non-cyclic dinucleotide small molecule STING agonists.
-
93 exclusive protected Chinese medicine varieties sold for 20 billion!
Time of Update: 2021-04-23
20 varieties of medical terminals sold over 100 million in half a year, and Naoxintong capsules won the first prize Table 3: Exclusive Chinese medicine protected varieties with sales exceeding 100 million yuan in 2020H1 Source: China Traditional Chinese Medicine Protected Varieties Catalog Database on Mynet According to data from Menet.
-
Pharmaceutical companies are named again for sales with gold
Time of Update: 2021-04-23
According to the above article, Liu Feng, the second-level inspector of the Bureau of Supervision and Evaluation of the Ministry of Finance, summarized from three aspects: “After inspection, he found out the cause of the falsely high drug prices, and deterred the illegal behavior of pharmaceutical companies to sell money and drive up prices.
-
Yuheng Pharmaceutical's Lugua Polypeptide was withdrawn from the Internet!
Time of Update: 2021-04-23
According to the requirements of the notice, since the date when the provincial medicine price and credit evaluation system for recruitment and procurement takes effect, pharmaceutical companies participating in or entrusting to participate in centralized procurement, online procurement, and filing procurement of drugs and medical consumables must submit a trustworthy commitment.
-
The fifth batch of centralized injections accounted for 50% of the four major cephalosporin antibiotics
Time of Update: 2021-04-23
cn/news/yyzb/" target="_blank">》，、。 ，35、、11，，，。 According to the normalized deployment of "centralized procurement twice a year", although biosimilar drugs and proprietary Chinese medicines have not yet appeared in the fifth batch of centralized procurement, whether it is the information released by the medical insurance bureau’s symposium or the normalized collection of the State Council From the perspective of opinions, it will be sooner or later that these types of products will be included in centralized procurement.
-
Pharmacies in Shanxi Province will resume sales of antipyretic drugs from April 16th
Time of Update: 2021-04-23
Medical Network News, April 19 Since April 16, pharmacies in Shanxi Province have resumed sales of antipyretic drugs. With immediate effect, pharmacies resume sales According to the "Notice on Str
-
The drug dealer issued a notice: a "4+7" quantity-collected product, difficult to purchase
Time of Update: 2021-04-23
For example, Hubei announced that the national organization of centralized drug procurement pilot expansion (Hubei) paroxetine oral constant-release dosage form and other 8 varieties of selected results also include dexmedetomidine hydrochloride injection.
-
Suzhou Dawnrays refused to supply cefmetazole sodium for injection after being exposed to the collection
Time of Update: 2021-04-23
On April 14, Zhejiang Province Pharmaceutical Equipment Procurement Center issued a "Notice on the Results of Procurement of Cefmetazole Injection Forms in Volume".
The "Notice" shows: According to the "Zhejiang Province Partial Drug Centralized Procurement Work Plan" (Zhejiang Medical Insurance Fa [2020] No.
-
Arnold Pharma announces the completion of the first patient dosing for Buparlisib's global phase III clinical trial
Time of Update: 2021-04-23
On April 15th, Arnold Pharma announced that its oral PI3K inhibitor Buparlisib (AN2025) combined with paclitaxel for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in the global multi-center phase III clinical trial has been successful in Shanghai Oriental Hospital, China Complete the first patient's administration.
-
State Council: Let go of the prescription drug sales online!
Time of Update: 2021-04-23
(Ministry of Civil Affairs, National Health Commission, State Drug Administration and other relevant departments of the State Council and various regions are responsible according to the division of responsibilities) Among them, “on the premise of ensuring the authenticity and reliability of the source of electronic prescriptions, online sales of prescription drugs other than those under special state management are allowed.
-
Announcement of annual results of Machinery Enterprise: Weigao, MicroPort, Yuyue...
Time of Update: 2021-04-23
2500%， ，iFinD，412，332020。 ，，2020，。 ，、，202047. 63，1203. 53%；26. 17，6527. 90%。 ，、、。 2020138. 37，564. 29%；70. 07，3829. 56%。，。 Previously, in the 2020 annual report performance forecast disclosed
